Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

@inproceedings{Tebas2015GreaterCI,
  title={Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks},
  author={Pablo Tebas and P Narindra Kumar and Charles B. Hicks and Catherine Granier and Brian R. Wynne and Sherene S. Min and Keith A. Pappa},
  booktitle={AIDS},
  year={2015}
}
OBJECTIVE Antiretroviral therapy initiation has been linked to bone mineral density and bone biomarker changes. We assessed long-term bone turnover biomarker effects over 144 weeks in patients initiating dolutegravir (DTG) + abacavir/lamivudine (ABC/3TC) versus efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). METHODS Patients randomized in SINGLE received DTG (50 mg once daily) + ABC/3TC or fixed-dose combination EFV/FTC/TDF. We evaluated vitamin D serum levels and bone… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Bone density changes after antiretroviral initiation with protease inhibitors or raltegravir

  • T Brown, C Moser, J Currier, H Ribaudo, J Rothenberg, M Dube
  • [Abstract 779LB]. 21st Annual Conference on…
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…